Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | La Merie | Competitor Analysis: Wet Age-Related Macular Degeneration (AMD)

Competitor Analysis: Wet Age-Related Macular Degeneration (AMD)

The present Competitive Intelligence Report about Wet and Dry Age-Related Macular Degeneration (AMD) provides a competitor evaluation in the field of R&D projects for treatment of AMD as of February 2009.

Macular degeneration in the elderly (“age-related macular degeneration”, AMD) is a major cause of blindness. Its prevalence increases to 30% in patients 75 to 85 years of age. AMD occurs in two forms: dry and wet AMD. Central geographic atrophy, the “dry” form of advanced AMD, results from atrophy to the retinal pigment epithelial layer below the retina, which causes vision loss through loss of photoreceptors (rods and cones) in the central part of the eye. While no treatment is available for this condition, vitamin supplements appear to slow the progression of dry macular degeneration and, in some patients, improve visual acuity. Neovascular or exudative AMD, the “wet” form of advanced AMD, causes vision loss due to abnormal blood vessel growth in the choriocapillaries, ultimately leading to blood and protein leakage below the macula. Bleeding, leaking, and scarring from these blood vessels eventually cause irreversible damage to the photoreceptors and rapid vision loss if left untreated.

It is only recently that new drugs have been approved for wet AMD which halt progression of the visual loss or even lead to improvement. The humanized antibody fragment ranibizumab (Lucentis) directed against vascular endothelial growth factor (VEGF) was developed by Genentech and Novartis has been approved in more than 70 countries worldwide since 2006 and posted record sales of US$ 1.76 bln in 2008.

The proven effectiveness and commercial success of the anti-VEGF treatment of wet AMD has encouraged many companies to develop new treatments of wet AMD based on the proven target VEGF as well as on other experimental approaches (anti-angiogenic, anti-proliferative, anti-inflammatory). More than 20 different approaches are in clinical development and more than 20 preclinical stage projecs are under evaluation for wet AMD. Among the projects are many biologics (antibodies, peptides, proteins, antisense, DNA, cells) facilitated by the topical (intravitreal administration). Small molecule approaches may confer the convenience of oral administration but efficacy still has to be demonstrated. Fewer projects are in clinical development for dry AMD, but the most prominent ones have reached advanced clinical testing, but definitive results are still lacking.

The report includes a compilation of marketed products and their sales in 2008 and current active projects in research and development of wet and dry AMD. In addition, the report lists company-specific product portfolios and R&D pipelines in AMD. Competitor projects are listed in a tabular format providing information on:

* Drug Codes,

* Target / Mechanism of Action,

* Class of Compound,

* Company,

* Product Category,

* Indication,

* R&D Stage and

* additional comments with a hyperlink leading to the source of information.

Index

* Sales of AMD Treatments in 2008

* Wet AMD

* Dry AMD

* Discontinued AMD Projects

* About La Merie

Corporate R&D Pipelines in AMD

* Acucela

* Adeona Pharmaceuticals

* Advanced Cell Technologies

* Advanced Refractory Technologies

* Alimera Sciences

* Allergan

* Angstrom Pharmaceuticals

* Arana Therapeutics

* Archemix

* Bayer Schering Pharma

* BioDiem

* BioInvent

* Catalyst Biosciences

* Cellgate

* ChemoCentryx

* CoMentis

* CSL

* Genentech

* GenVec

* GlaxoSmithKline (GSK)

* iCo Therapeutics

* Iconic Therapeutics

* Jerini Ophthalmics

* Johnson & Johnson (J&J)

* KAI Pharmaceuticals

* LPath

* MacuSight

* Neurotech

* NIH (National Institutes of Health)

* Novartis (Ophthalmics)

* OccuLogix

* Ophthotech

* OPKO Health

* Ora Bio

* OSI Pharmaceuticals

* Othera Pharmaceuticals

* Otsuka Pharmaceuticals

* Oxford Biomedicals

* Oxigene

* Potentia Pharmaceuticals

* Pfizer

* Pieris

* Quark Pharmaceuticals

* QLT

* Regeneron Pharmaceuticals

* Sangamo Biosciences

* Santen

* Sirion Therapeutics

* Sirna Therapeutics

* StemCells

* TargeGen

* ToolGen

* TRACON Pharmaceuticals

About Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Publisher: La Merie

Product Line: Competitor Analysis

Pages: 43

Release Date: February of 2009

Format: PDF

Product Code: LMCA0086

Price

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions